Intellectual Property Rights and Access to Innovation: Evidence from Trips
@article{Kyle2014IntellectualPR, title={Intellectual Property Rights and Access to Innovation: Evidence from Trips}, author={Margaret Kyle and Yi Qian}, journal={Kauffman: Large Research Projects (Topic)}, year={2014} }
We examine the effect of pharmaceutical patent protection on the speed of drug launch, price, and quantity in 60 countries from 2000-2013. The World Trade Organization required its member countries to implement a minimum level of patent protection within a specified time period as part of the TRIPS Agreement. However, members retained the right to impose price controls and to issue compulsory licenses under certain conditions. These countervailing policies were intended to reduce the potential…
35 Citations
Do Patents Work? Thickets, Trolls and Antibiotic Resistance
- Economics
- 2017
This paper connects ideas from recent literature on the economics of intellectual property (IP) to address the question: Did the strengthening and broadening of IP rights from important patent policy…
Patent protection in developing countries and global welfare: WTO obligations versus flexibilities
- Economics
- 2020
Patents, trade and medicines: past, present and future
- EconomicsReview of International Political Economy
- 2019
Abstract This article analyzes the spread of intellectual property in trade agreements. We explain how the integration of intellectual property with international trade rules led to the globalization…
The hidden cost of low prices: limited access to new drugs in India.
- Economics, Political ScienceHealth affairs
- 2014
It is concluded that modest patent and regulatory reform could bring the faster availability of a wider range of new drugs in India with limited impact on prices--a trade-off that merits greater policy attention.
The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India
- Economics
- 2014
In 2005, as the result of a World Trade Organization mandate, India began to implement product patents for pharmaceuticals that were compliant with the 1995 Trade-Related Aspects of Intellectual…
Does Regulation Drive International Research Cooperation? Evidence from the Pharmaceutical Sector
- BusinessThe World Economy
- 2018
To what extent is an increased stringency of the Intellectual Property Rights (IPR) system apt to stimulate research cooperation between developed and emerging economies? To address this question, we…
Intellectual Property Rights and Innovation: Evidence from Health Care Markets
- EconomicsInnovation Policy and the Economy
- 2016
A long theoretical literature has analyzed optimal patent policy design, yet there is very little empirical evidence on a key parameter needed to apply these models in practice: the relationship…
Global drug diffusion and innovation with the medicines patent pool.
- EconomicsJournal of health economics
- 2022
Value Appropriation and New Product Pricing: A Study of New Prescription Drugs
- Business
- 2021
Value appropriation, or a firm’s ability to collect economic rents from its offerings, tools can erect barriers to competition and influences firm profitability. Patent protections are widely used…
References
SHOWING 1-10 OF 35 REFERENCES
Do Patents Matter?: Empirical Evidence after GATT
- Political Science
- 2000
Since the late 1980s the global intellectual property rights (IPR) system has been strengthening dramatically as much of the developing world introduces patent protection for new drug products. This…
Investments in Pharmaceuticals Before and After TRIPS
- EconomicsReview of Economics and Statistics
- 2012
Abstract The TRIPS Agreement, which specifies minimum levels of intellectual property protection for countries in the WTO, has increased levels of patent protection around the world. Using variation…
Diffusion of New Drugs in the Post-TRIPS Era
- Political Science
- 2011
Abstract We examine the international diffusion of new drugs under the post-TRIPS intellectual property rights regime. Even after controlling for drug characteristics and variation in national health…
The hidden cost of low prices: limited access to new drugs in India.
- Economics, Political ScienceHealth affairs
- 2014
It is concluded that modest patent and regulatory reform could bring the faster availability of a wider range of new drugs in India with limited impact on prices--a trade-off that merits greater policy attention.
The Role of Firm Characteristics in Pharmaceutical Product Launches
- Business
- 2006
This paper examines the determinants of new pharmaceutical launches since 1980 in the G7 nations using discrete-time hazard models. Despite the obvious incentive to amortize the large sunk costs of…
The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India
- Economics
- 2014
In 2005, as the result of a World Trade Organization mandate, India began to implement product patents for pharmaceuticals that were compliant with the 1995 Trade-Related Aspects of Intellectual…
The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries
- Economics
- 2014
We use dynamic panel data regressions to investigate whether the strength of a country’s patent protection for pharmaceuticals is associated with more pharmaceutical patenting by its residents and…
The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s
- EconomicsHealth economics
- 2005
The results indicate that countries with lower expected prices or smaller expected market size have fewer launches and longer launch delays, controlling for per capita income and other country and firm characteristics.
Do Stronger Intellectual Property Rights Increase International Technology Transfer? Empirical Evidence from U.S. Firm-Level Panel Data
- Economics
- 2004
One of the alleged benefits of the recent global movement to strengthen intellectual property rights (IPRs) is that such reforms accelerate transfers of technology between countries. The paper…